Pharmaceutical companies understand that the current environment demands a different approach to drug development, especially during start up, where missteps are likely to interfere with overall success. A targeted, data-driven approach that considers the therapeutic, protocol and country level regulatory detail together with historical country and site performance is likely to be more successful. An approach to assess the best fit countries and associated sites for particular trials includes accessing a comprehensive site performance database, tapping into global resources, choosing the most relevant data, and using analytical algorithms to forecast outcomes.